medigraphic.com
Colegio de Medicina Interna de México.

2019, Number 6

<< Back Next >>

Med Int Mex 2019; 35 (6)

IgG antibody against anticitrullinated peptide/proteins antigens in early and very early rheumatoid arthritis and its role in the diagnosis and disease activity

Mercado U, Barrientos V, Mercado H

Language: Spanish
References: 21
Page: 871-876
PDF size: 432.11 Kb.


ABSTRACT

Objective: To compare the diagnostic utility of IgG antibodies against citrullinated peptide/proteins antigens (PCC) in early rheumatoid arthritis ≤ 12 months and very early rheumatoid arthritis ≤ 6 months versus rheumatoid factor and to establish a relationship with active disease.
Material and Method: A retrospective observational study done from January to December 2017 with data collected from the clinical and laboratory records of patients with rheumatoid arthritis. Serum levels of anti-CCP2 › 20 U/mL and rheumatoid factor by latex › 1:80 were the cut-off points. The disease activity was measured using DAS28/ ESR and the clinical disease activity index (CDAI).
Results: There were included 246 patients (34 men, 212 women, median age 44). Sensitivity, specificity, and likelihood ratio (+) for anti-CCP of 246 patients were 71%, 97% and 23.6 versus 50%, 92% and 6.7 for rheumatoid factor, respectively. No correlation was found between anti-CCP and DAS28 in 57 patients with ESR (r = 0.07) or CDAI (r = 0.13), while a good correlation was found between DAS28 and CDAI (r = 0.79).
Conclusion: The single measurement of anti-CCP is useful for the diagnosis of the disease; however, the combination with the rheumatoid factor is very useful. Although anti-CCP has been implicated in the pathogenesis of rheumatoid arthritis, no correlation was found between anti-PCC and DAS28/ESR, or CDAI but it was between DAS28/ VSG and CDAI.


REFERENCES

  1. Fox DA. Citrullination: a specific target for the autoimmune response in rheumatoid arthritis. J Immunol 2015;195:195:5-7. DOI: https://doi.org/10.4049/jimmunol. 1501021.

  2. Schellenkens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-281. doi: 10.1172/JCI1316.

  3. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Miglioni P. Deiminated Epstein-Barr Virus Nuclear Antigen 1 Is a Target of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis. Arthritis Rheum 2006;54:733-741. DOI: 10.1002/art.21629.

  4. Muller S, Radic M. Citrullinated autoantigens:From diagnostic markers to pathogenetic mechanisms. Clin Rev Allergy Immunol 2015;49:232-9. doi: 10.1007/s12016- 014-8459-2.

  5. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstrom V, Feldmann M et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010;233:34-54. doi: 10.1111/j.0105-2896.2009.00850.x.

  6. Holers VM. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Immunol 2013;25:728-735. doi: 10.1016/j.coi.2013.09.018.

  7. Nishimura K, Sugiyama D, Tesuji Y, Nakasawa T, Kawano S, Saigo K et al. Meta-Analysis: Diagnostic accuracy of anticyclic citrulline peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:11:797- 808. DOI: 10.7326/0003-4819-146-11-200706050-00008.

  8. Whiting PF, Smidt N, Sterne JAC, Harbord R, Burton A, Burke M et al. Systematic review. Accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152:456-464. doi: 10.7326/0003- 4819-152-7-201004060-00010.

  9. Vanichapuntu M, Phuekfon P, Suwannalai V, Verasertniyom V, Nantiruj K, Janwityanuju S. Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population? Rheumatol Int 2010;30:755-759. doi: 10.1007/s00296-009-1058-5.

  10. Sakkas L, Valopoulos G, Bogdanos DP. Citrullinated proteins are arthritogenic autoantigens in rheumatoid arthritis. Am J Arthritis Res 2017;1:1-4. doi: 10.1016/j. autrev.2014.08.012.

  11. Santos Porto LS, Tavares Junior WC, da Silva Costa DA, Duarte Lanna CC, Kakehasi AM. Anti-CCP antibodies are not a marker of severity in established rheumatoid arthritis; a magnetic resonance imaging study. Rev Bras Rheumatol 2017;57:15-22. Doi: 10.1016/j.rbre.2015.07.018.

  12. Aletaha D, Neogi T, Silman, AJ, Funovits JU, Felson DT et al. 2010 rheumatoid arthritis classification criteria. An American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-2581. doi: 10.1002/art.27584.

  13. Tanaka R, Takemura M, Sato M, Yamada Y, Nakagawa T, Horibe T et al. Comparison of chemiluminescence enzyme immunoassay (CLIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies. Clin Chim Acta 2010;411:22-5. doi: 10.1016/j.cca.2009.09.032.

  14. Egerer K, Feist E, Burmester GR. The serological diagnosis of rheumatoid arthritis. Desch Arztebl 2009;106:159-163. doi: 10.3238/arztebl.2009.0159.

  15. Deeks JJ, Altman DG. Diagnostic tests 4. Likelihood ratios. BMJ 2004;329:168-9. DOI: 10.1136/bmj.329.7458.168.

  16. Hayden SR, Brown MD. Likelihood ratio: a powerful tool for incorporating the results of a diagnostic test into clinical decision making. Ann Emerg Med 1999;33:575-580. DOI: 10.1016/S0196-0644(99)70346-X.

  17. Landmann T, Kehl G, Bergner R. The continuous measurement of anti-CCP antibodies does not help to evaluate the disease activity in anti-CCP antibody-positive patients with rheumatoid arthritis. Clin Rheumatol 2010;12:1449-53. doi: 10.1007/s10067-010-1557-5.

  18. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/ peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749. 8. DOI: 10.1136/ard.2004.033571.

  19. Serdaroglu M, Cakirbay H, Deger O, Cengiz S, Kul S. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 2008;28:965-970. doi: 10.1007/s00296-008-0570-3.

  20. Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G et al. Mutation and citrulination modifies vimenti to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-2511. DOI: 10.1002/art.22817.

  21. Ursum J, Nielen MMJ, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BAC et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008;10:R12. DOI: 10.1186/ar2362.




2020     |     www.medigraphic.com